menu
    • menu
    [{"orgOrder":0,"company":"Pyros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vigabatrin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pyros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pyros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pyros Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Pyros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vigabatrin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pyros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Pyros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pyros Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Pyros Pharmaceuticals","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Vigabatrin","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pyros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Pyros Pharmaceuticals \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Pyros Pharmaceuticals \/ Bora Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Pyros Pharmaceuticals

    Menu

    Pyros Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pyros Pharmaceuticals

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Pyros Pharmaceuticals

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vigabatrin

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Bora Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bora Expands Rare Disease Portfolio with Pyros Pharma Acquisition

                            Details : Through the acquisition of US-based Pyros, Bora will expand his pipelines by adding some candidates such as Vigafyde (vigabatrin), which is indicated for the treatment of infantile spasms.

                            Product Name : Vigafyde

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 25, 2024

                            Lead Product(s) : Vigabatrin

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Bora Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pyros Pharmaceuticals

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Pyros Pharmaceuticals

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vigabatrin

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pyros Pharmaceuticals: FDA Approves VIGAFYDE as Ready-to-Use Oral Solution

                            Details : Vigafyde (vigabatrin) is approved as monotherapy for pediatric patients with refractory complex partial seizures or infantile spasms in patients 1 month to 2 years of age.

                            Product Name : Vigafyde

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 17, 2024

                            Lead Product(s) : Vigabatrin

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pyros Pharmaceuticals

                            U.S.A arrow
                            ELCC
                            Not Confirmed

                            Pyros Pharmaceuticals

                            U.S.A arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vigabatrin

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pyros Pharmaceuticals Reports Positive Outcome in European Procedure for VIGZIP™ Approval

                            Details : Vigzip (vigabatrin) is a Gamma-amino-N-butyrate transaminase inhibitor, which is indicated for the treatment of patients with infantile spasms (West's syndrome).

                            Product Name : Vigzip

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 15, 2024

                            Lead Product(s) : Vigabatrin

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth